These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 30865483)
1. Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial. Jia X; Akeroyd JM; Nasir K; Nambi V; Ballantyne CM; Petersen LA; Virani SS Circulation; 2019 Mar; 139(10):1341-1343. PubMed ID: 30865483 [No Abstract] [Full Text] [Related]
2. Icosapent ethyl: Where will it fit into guideline-based medical therapy for high risk atherosclerotic cardiovascular disease? Orringer CE Trends Cardiovasc Med; 2020 Apr; 30(3):151-157. PubMed ID: 31101399 [TBL] [Abstract][Full Text] [Related]
3. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Jellinger PS; Smith DA; Mehta AE; Ganda O; Handelsman Y; Rodbard HW; Shepherd MD; Seibel JA; Endocr Pract; 2012; 18 Suppl 1():1-78. PubMed ID: 22522068 [No Abstract] [Full Text] [Related]
4. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis: executive summary. Jellinger PS; Smith DA; Mehta AE; Ganda O; Handelsman Y; Rodbard HW; Shepherd MD; Seibel JA; Endocr Pract; 2012; 18(2):269-93. PubMed ID: 22507559 [No Abstract] [Full Text] [Related]
6. Icosapent ethyl for treatment of elevated triglyceride levels. Nelson SD; Munger MA Ann Pharmacother; 2013 Nov; 47(11):1517-23. PubMed ID: 24259598 [TBL] [Abstract][Full Text] [Related]
7. The Role of n-3 Fatty Acids in Cardiovascular Disease: Back to the Future. Perez-Martinez P; Katsiki N; Mikhailidis DP Angiology; 2020 Jan; 71(1):10-16. PubMed ID: 30966756 [TBL] [Abstract][Full Text] [Related]
8. Clinical Lipidology and the Prevention of Vascular Disease: Time for Personalized Therapy. Brown WV Clin Pharmacol Ther; 2018 Aug; 104(2):269-281. PubMed ID: 29998536 [TBL] [Abstract][Full Text] [Related]
9. News from ESC congress 2019: New ESC/EAS guidelines for dyslipidaemia management published. Stock J Atherosclerosis; 2019 Dec; 291():124-126. PubMed ID: 31668350 [No Abstract] [Full Text] [Related]
10. Potential benefits of eicosapentaenoic acid on atherosclerotic plaques. Nelson JR; Wani O; May HT; Budoff M Vascul Pharmacol; 2017 Apr; 91():1-9. PubMed ID: 28263852 [TBL] [Abstract][Full Text] [Related]
12. Biologic bases of residual risk of cardiovascular events: A flawed concept. Shapiro MD; Fazio S Eur J Prev Cardiol; 2018 Nov; 25(17):1831-1835. PubMed ID: 30196721 [No Abstract] [Full Text] [Related]
13. Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome. Bays HE; Ballantyne CM; Braeckman RA; Stirtan WG; Doyle RT; Philip S; Soni PN; Juliano RA Metab Syndr Relat Disord; 2015 Aug; 13(6):239-47. PubMed ID: 25893544 [TBL] [Abstract][Full Text] [Related]
14. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Borow KM; Nelson JR; Mason RP Atherosclerosis; 2015 Sep; 242(1):357-66. PubMed ID: 26253795 [TBL] [Abstract][Full Text] [Related]
15. Improving lipids with prescription icosapent ethyl after previous use of fish oil dietary supplements. Reddy KJ; Chowdhury S Future Cardiol; 2016 May; 12(3):261-8. PubMed ID: 27070379 [TBL] [Abstract][Full Text] [Related]
16. National Trends in Nonstatin Use and Expenditures Among the US Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel Survey. Salami JA; Warraich HJ; Valero-Elizondo J; Spatz ES; Desai NR; Rana JS; Virani SS; Blankstein R; Khera A; Blaha MJ; Blumenthal RS; Katzen BT; Lloyd-Jones D; Krumholz HM; Nasir K J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29358195 [TBL] [Abstract][Full Text] [Related]
17. New trials in the scene of cardiovascular disease: innovation, controversy, and reassurance. Badimon L Cardiovasc Res; 2021 Mar; 117(4):e52-e54. PubMed ID: 33615348 [No Abstract] [Full Text] [Related]